Aroa Biosurgery’s Myriad product family was a star performer of the company’s first profit since listing in 2020 and is ...

In addition to further validating the use of Myriad products in these challenging lower extremity reconstructions [2], the study highlights the potential for significant cost benefits.

Aroa Biosurgery Ltd (AU:ARX) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top StocksMake ...

Special Report: Aroa Biosurgery is targeting the growing lower-limb surgical salvage market with its Myriad family of products, which have been a strong performer for the company and can be used ...